Dose expression of anticancer drugs;Expression de la posologie des medicaments anticancereux

Revue de Medecine Interne

Volumn 17, Issue 7, 1996, Pages 586-596

  Favre, R ^a   Duffaud, F ^a   Erard G ^b  

^a TIMONE HOSPITAL   (France)

^b Laboratoire Pharmacia   (France)

Author keywords

anticancer drugs; body surface area; dosage adaptation

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CISPLATIN; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; PIRARUBICIN; VINBLASTINE; VINCRISTINE; VINDESINE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DOSE CALCULATION; DRUG CLEARANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; PLASMA CLEARANCE; SCHOOL CHILD;

EID: 0030200141     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/0248-8663(96)83098-0     Document Type: Article

References (21)

1. 1 Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18:853-6
2. 2 Freireich EJ, Gehan EA, Rall DP et al. Quantitative comparaison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 1966;50:219-44
3. 3 Lam TK, Leung DTY. More on simplified calculation of body surface area. N Engl J Med 1988;318:1130
4. 4 Mosteller RD, Simplified calculation of body surface area from height and weight. N Engl J Med 1987;317:1088
5. 5 Vriesendrop HM. Optimal prescription method for cancer chemotherapy. Exp Hematol 1985:13:57-63
6. 6 Vriesendrop HM, Vriesendrop R, Vriesendrop FJ. Prediction of normal tissue damage induced by chemotherapy. Cancer Chemother Pharmacol 1987;19:273-6
7. 7 Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia: Lea & Febiger, 1980
8. 8 Liliemark J. Pharmacokinetic studies on Ara-C with specials emphasis on the cellular pharmacokinetics. Scand J Haematol 1986;36:41-51
9. 9 Gilles E, Zambon E, Ostronnof M et al. Cytarabine dosage adaptation: requirement for a dynamic approach. Proceedings ECCO, Londres, 1990
10. 10 Robert J, Bui NB, Vrignaud P. Pharmacokinetics of doxorubicin in sarcoma patients. Eur J Clin Pharmacol 1987;31:695-9
11. 11 Mac Vie GJ. The role of pharmacokinetics in (combination) chemotherapy. Cancer 1984;54:1175-8
12. 12 Tranchand B, Serre-Debeauvais F. Adaptation de posologie en cancérologie : aspects méthodologiques et applications cliniques. In: Bres J, Panis G, eds. Pharmacocinétique : de la recherche à la clinique. Paris : John Libbey Eurotext, 1992:55-71
13. 13 Favre R, Charbit M, Rinaldi Y, Iliadis A, Cano JP, Carcassonne Y. La pharmacocinétique dans les études de phase IV pour la précision du schéma thérapeutique. Bull Cancer 1988;75:541-50
14. 14 Milano G. L'adaptation de posologie des anticancéreux dans sa réalité pratique. Bull Cancer 1993;80:374-5
15. 15 Desoize B. À quel critère faut-il adapter la posologie des anticancéreux ? Bull Cancer 1993;80:376-90
16. 16 Lokich, JJ. Cancer chemotherapy by infusion. Chicago: Precept Press Inc, 1990
17. 17 Gamelin E, Paillard P, Burtin P et al. Effet-dose dans les carcinomes colorectaux métastatiques : intérêt de l'adaptation de posologie du 5-fluorouracile (5-FU) à hautes doses associé à l'acide folinique (AF). Bull Cancer 1992;79:632
18. 18 Hryniuk WH. Average relative dose intensity and the impact on the design of clinical trials. Semin Oncol 1987;14:65-74
19. es Entretiens Servier en cancérologie. Méthodologie de la recherche clinique en cancérologie : réflexions et perspectives, 1994:12-8
20. 20 Delepine N, Delepine G, Cornille H et al. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 1995;15:489-94
21. 21 Favre R. Du laboratoire de recherche au laboratoire de routine. Réflexions sur la transfert de technologie à propos de la chimiorésistance. Bull Cancer 1994;81:112-4